|
Beta-Blocker Evaluation in Survival Trial (BEST) Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on Beta-Blocker Evaluation in Survival Trial (BEST) conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Beta-Blocker Evaluation in Survival Trial (BEST) Clinical research trials and Beta-Blocker Evaluation in Survival Trial (BEST) health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Beta-Blocker Evaluation in Survival Trial (BEST). Beta-Blocker Evaluation in Survival Trial (BEST) Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Beta-Blocker Evaluation in Survival Trial (BEST) clinical trial. Participants oftentimes recieve the most expert healthcare available for their Beta-Blocker Evaluation in Survival Trial (BEST) condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "B" Clinical Trials Conditions > Beta-Blocker Evaluation in Survival Trial (BEST)  Beta-Blocker Evaluation in Survival Trial (BEST)
Beta-Blocker Evaluation in Survival Trial (BEST)
For Condition: Cardiovascular Diseases,Heart Diseases,Heart Failure, Congestive,Heart Failure
Status: Completed
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To determine if addition of a beta-blocker to standard therapy in Class III and Class IV heart failure patients reduced total mortality.
Details: BACKGROUND: Controlled and uncontrolled studies suggested that beta-blockade improves ventricular function in congestive heart failure. Several trials suggested that beta-blockers may also reduce mortality. In the Beta-Blocker Heart Attack Trial, patients with a history of heart failure had less cardiac and sudden-death mortality than those who did not. Patients with a low ejection fraction in the Cardiac Arrhythmia Suppression Trial who were treated with beta-blockade also had a reduction in mortality. The Metoprolol in Dilated Cardiomyopathy trial randomized patients with dilated cardiomyopathies to treatment with metoprolol or placebo. There was a trend toward reduction in a morbidity and mortality endpoint in patients treated with metoprolol, but this was due entirely to a reduction in the need for cardiac transplantation. Thus, despite a reasonable theoretical basis and suggestive clinical studies, the concept that beta-blockers reduced mortality in congestive heart failure patients was unproved. DESIGN NARRATIVE: Randomized, double-blind, multicenter. Patients were assigned to standard therapy plus the addition of a beta-blocker (bucindolol) versus a placebo. The primary endpoint was total mortality. A radionuclide ventriculogram was performed within 60 days of randomization. History, physical examination, clinical laboratory studies, chest x-ray, electrocardiogram, and plasma norepinephrine levels were obtained within 14 days of randomization. Patients were stratified by hospital, congestive heart failure etiology, ejection fraction, and gender, and were assigned to a treatment group by an adaptive balancing scheme ("biased coin" randomization). Patients were randomized to either placebo plus standard congestive heart failure treatment or to the beta-blocker plus standard congestive heart failure treatment and followed for a minimum of 18 months. The over three year recruitment period began in May 1995 at the first 35 sites. An additional 55 sites began recruitment on August 14, 1995. Recruitment ended in December, 1998 with the enrollment of 2,708 patients.
Eligibility:
Study Type: Interventional, Randomized, Double-Blind, Placebo Control
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Men and women, ages 18 and over. Patients had compensated congestive heart failure due to idiopathic dilated cardiomyopathy or coronary disease with ejection fraction less than or equal to 0.35, were in the New York Heart Association functional class III or IV, and were taking an angiotensin-converting enzyme inhibitor, digitalis, and if needed, a diuretic. Patients with a specific indication for, or contraindication to, beta-blockade were excluded.
Total Enrollment:
Location and Contact Information:
Overall Study Official:
PhilipLavori, , Veterans Administration Hospital
Additional Information:
Study ID Numbers: 104;
Study Start Date: June 1994
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000560
Other Cardiovascular Diseases Studies:
1. Women's Ischemia Syndrome Evaluation (WISE)
2. Antecedents of the Type A Behavior Pattern
3. Bypass Angioplasty Revascularization Investigation in Type 2 Diabetics (BARI 2D)
4. Dietary Patterns, Sodium Intake and Blood Pressure (DASH - Sodium)
5. Hematocrit Strategy in Infant Heart Surgery
Related Studies:
Other Cardiovascular Diseases Clinical Trials
Other Clinical Trials
Other Clinical Trials
Beta-Blocker Evaluation in Survival Trial (BEST)
|
|
|
|
|
|
|
|
